Evidence map›Paper›PMID 36444225›Full record

ArticleJACC. CardioOncology2022

Low QRS Voltages in Cardiac Amyloidosis: Clinical Correlates and Prognostic Value.

Alberto Cipriani, Laura De Michieli, Aldostefano Porcari, Luca Licchelli, Giulio Sinigiani, Giacomo Tini, Mattia Zampieri, Eugenio Sessarego, Alessia Argirò, Carlo Fumagalli and 15 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. CardioOncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 7 institutions in 1 country.

Alberto CiprianiDepartment of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Laura De MichieliDepartment of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Aldostefano PorcariCenter for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina, University of Trieste, Trieste, Italy.
Luca LicchelliDepartment of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Giulio SinigianiDepartment of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Giacomo TiniDepartment of Clinical and Molecular Medicine, Sapienza University, Rome, Italy.
Mattia ZampieriTuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy.
Eugenio SessaregoDepartment of Internal Medicine, University of Genova, Genova, Italy.
Alessia ArgiròTuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy.
Carlo FumagalliTuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy.
Monica De GaspariDepartment of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Roberto LicordariDepartment of Cardiology, University of Messina, Messina, Italy.
Domitilla RussoDepartment of Clinical and Molecular Medicine, Sapienza University, Rome, Italy.
Gianluca Di BellaDepartment of Cardiology, University of Messina, Messina, Italy.
Federico PerfettoTuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy.
Camillo AutoreDepartment of Clinical and Molecular Medicine, Sapienza University, Rome, Italy.
Beatrice MusumeciDepartment of Clinical and Molecular Medicine, Sapienza University, Rome, Italy.
Marco CanepaDepartment of Internal Medicine, University of Genova, Genova, Italy.
Marco MerloCenter for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina, University of Trieste, Trieste, Italy.
Gianfranco SinagraCenter for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina, University of Trieste, Trieste, Italy.
Dario GregoriDepartment of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Sabino IlicetoDepartment of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Martina Perazzolo MarraDepartment of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Francesco CappelliTuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy.
Claudio RapezziCardiothoracic Department, University of Ferrara, Ferrara, Italy.
University of Padua · ITAzienda Ospedaliero-Universitaria Careggi · ITSapienza University of Rome · ITUniversity of Trieste · ITUniversity of Messina · ITOspedale Policlinico San Martino · ITUniversity of Genoa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Low QRS voltages (LQRSVs) are a common electrocardiographic feature in patients with light chain amyloidosis (AL) and transthyretin amyloidosis (ATTR) cardiac amyloidosis (CA). Objectives: The aim of this study was to identify clinical and echocardiographic correlates of LQRSV and to investigate their prognostic significance in patients with CA. Methods: This was a multicenter, retrospective study performed in 6 CA referral centers including consecutive patients with AL and ATTR CA. LQRSVs were defined as a QRS amplitude ≤5 mm (0.5 mV) in all peripheral leads. The study outcome was cardiovascular (CV) mortality. Results: Overall, 411 (AL CA: n = 120, ATTR CA: n = 291) patients were included. LQRSVs were present in 66 (55%) patients with AL CA and 103 (35%) with ATTR CA ( Conclusions: LQRSVs are common but not ubiquitous in CA; they are more frequent in AL CA than in ATTR CA. LQRSVs reflect an advanced disease stage and independently predict CV death. In ATTR CA, LQRSVs can provide incremental prognostic accuracy over the NAC staging system in patients with intermediate risk.

Indexed as

AL, light chain amyloidosisATTR, transthyretin amyloidosisATTR-v, variant transthyretinATTR-wt, wild-type transthyretinAUC, area under the curveBNP, B-type natriuretic peptideCA, cardiac amyloidosiscardiac amyloidosisCMR, cardiac magnetic resonanceCV, cardiovascularECG, electrocardiogramechocardiographyelectrocardiographylow QRS voltagesLQRSV, low QRS voltagesLVEDD, left ventricular end-diastolic diameterLV, left ventricleNAC, National Amyloidosis CentreNT-proBNP, N-terminal pro–B-type natriuretic peptideNYHA, New York Heart Associationprognostic significancerisk stratificationROC, receiver-operating characteristicRV, right ventricularTAPSE, tricuspid annulus peak systolic excursion

Identifiers

PMID36444225
PMCPMC9700257
OpenAlexW4294875898

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.